Sight Sciences, Inc. (SGHT) Key Metrics

NASDAQ: SGHTValuation, returns, debt and efficiency ratios over 8 years.

SGHT valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$456.1M
Enterprise value
$431.0M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
5.5
10-yr median 5.3
Price / book
8.9
10-yr median 3.6
EV / EBITDA
—
Dividend yield
—
Beta
2.45

SGHT key metrics, 2018–2025

Fiscal year ended December 31, 2025 · U.S. dollars

SGHT valuation Price multiples at each fiscal year-end price.

Price / sales+133.9%
5.3
2025 · hover or tap a bar for each year
2021: 17.02022: 8.2 (−52.0%)2023: 3.1 (−62.2%)2024: 2.3 (−26.2%)2025: 5.3 (+133.9%)
20182025
Price / book+210.2%
6.5
2025 · hover or tap a bar for each year
2021: 3.62022: 3.6 (+1.5%)2023: 2.1 (−42.8%)2024: 2.1 (−0.1%)2025: 6.5 (+210.2%)
20182025
Free cash flow yield+5.2 pts
−7.2%
2025 · hover or tap a bar for each year
2021: −6.4%2022: −13.2% (−6.8 pts)2023: −19.1% (−6.0 pts)2024: −12.5% (+6.7 pts)2025: −7.2% (+5.2 pts)
20182025

SGHT valuation history

Fiscal year-endToday8-year median

SGHT returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

SGHT debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

SGHT cash returned to shareholders

DividendsBuybacksFree cash flow

SGHT price vs earnings per share

Share price at year-endEPS (right axis)

SGHT key metrics

2018–2025
Sight Sciences, Inc. key metrics by fiscal year
20252024202320222021202020192018
Valuation
Market capitalization$413.5M$182.5M$250.9M$584.2M$834.7M———
Enterprise value$362.3M$102.5M$148.2M$434.2M$607.1M———
Price / sales5.32.33.18.217.0———
Price / book6.52.12.13.63.6———
EV / sales4.71.31.86.112.4———
Earnings yield−9.3%−28.2%−22.1%−14.8%−7.5%———
Free cash flow yield−7.2%−12.5%−19.1%−13.2%−6.4%———
Shareholder yield (dividends + buybacks)——0.1%0.0%0.0%———
Share price at fiscal year-end$7.93$3.64$5.16$12.21$17.57———
Per share
Revenue per share$1.48$1.59$1.67$1.49$1.03$0.59$0.69$0.23
Earnings per share−$0.74−$1.03−$1.14−$1.80−$1.33−$0.74−$0.77−$0.44
Operating cash flow per share−$0.57−$0.45−$0.97−$1.59−$1.11−$0.69−$0.74−$0.45
Free cash flow per share−$0.57−$0.45−$0.99−$1.61−$1.12−$0.71−$0.76−$0.47
Cash per share$1.76$2.40$2.84$3.87$5.49$1.32$0.63$0.13
Book value per share$1.23$1.75$2.47$3.35$4.89−$1.90−$1.63−$0.90
Tangible book value per share$1.23$1.75$2.47$3.35$4.89−$1.90−$1.63−$0.90
Capex per share$0.00$0.01$0.02$0.02$0.02$0.02$0.02$0.02
Debt per share$0.78$0.81$0.73$0.73$0.70$0.69$0.41$1.06
Shares outstanding52.1M50.1M48.6M47.8M47.5M46.8M33.6M32.2M
Change in shares outstanding+4.0%+3.1%+1.6%+0.7%+1.6%+39.1%+4.4%—
Returns & profitability
Return on equity (ROE)−50.7%−49.6%−39.6%−44.0%−87.9%———
Return on invested capital (ROIC)−289.0%−319.0%−328.4%−905.9%————
Return on assets (ROA)−29.8%−33.3%−29.3%−35.0%−35.7%−67.0%−133.2%−176.6%
Return on tangible assets−33.3%−36.1%−33.3%−40.5%−22.5%−47.7%−84.2%−176.6%
Free cash flow margin−38.7%−28.5%−59.2%−107.9%−109.0%−119.9%−109.9%−199.8%
Financial health
Total debt$40.8M$40.4M$35.4M$35.0M$33.2M$32.5M$13.9M$34.2M
Cash & short-term investments$92.0M$120.4M$138.1M$185.0M$260.7M$61.5M$21.2M$4.2M
Net debt−$51.2M−$80.0M−$102.7M−$150.0M−$227.5M−$29.0M−$7.3M$29.9M
Debt / equity0.640.460.290.220.14———
Debt / assets0.350.280.210.160.120.450.454.22
Current ratio10.229.0413.2911.7720.527.583.822.47
Quick ratio9.528.6312.6511.4320.267.303.512.31
Interest coverage-7.2-10.8-10.6-18.8-11.8-13.4-12.3—
Working capital$101.7M$124.3M$150.6M$191.9M$263.5M$61.3M$20.7M$4.3M
Invested capital$12.8M$7.5M$17.5M$10.1M$4.6M−$117.9M−$62.0M$949,000
Tangible asset value$63.9M$87.5M$120.2M$160.1M$232.1M−$88.8M−$54.7M−$29.0M
Net current asset value$61.4M$84.5M$116.4M$156.7M$229.0M−$91.0M−$57.4M−$29.9M
Graham net-net per share$0.99$1.52$2.19$3.06$4.65−$2.03−$1.78−$0.97
Capital allocation
Share buybacks (net)——$224,000$0$0———
Capex / revenue0.3%0.5%1.0%1.4%1.7%3.4%2.9%7.6%
Capex / depreciation0.460.541.291.371.291.722.289.05
Stock-based compensation / revenue16.9%21.4%18.0%18.2%10.4%1.8%0.5%0.7%
R&D / revenue18.9%22.5%21.7%32.0%31.9%32.1%34.8%72.1%
SG&A / revenue115.2%126.2%134.3%168.3%155.6%151.0%140.1%186.8%
Efficiency
Days sales outstanding48.457.366.361.052.562.446.288.0
Days of inventory on hand240.4223.4214.5141.6128.796.076.175.9
Days payables outstanding51.853.967.989.2116.888.6117.0293.3
Cash conversion cycle (days)237.1226.7212.9113.564.469.85.4-129.5
Receivables turnover7.546.375.515.986.965.857.904.15
Payables turnover7.056.775.384.093.134.123.121.24
Inventory turnover1.521.631.702.582.843.804.794.81
Asset turnover0.600.520.430.290.280.531.200.93
Average receivables$10.3M$12.5M$14.7M$11.9M$7.0M$4.7M$3.0M$1.8M
Average payables$1.5M$1.7M$2.2M$3.0M$2.8M$2.2M$2.1M$1.9M
Average inventory$7.0M$7.1M$7.0M$4.8M$3.0M$2.4M$1.4M$486,000
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Computed from SGHT's annual financial statements (latest annual report filed March 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

SGHT valuation and financial ratios

Sight Sciences earned a return on equity of −50.7% and a return on invested capital of −289.0% in fiscal 2025. It ended the year with $40.8 million of debt and $92.0 million in cash and short-term investments, a net cash position of $51.2 million. The share count rose 61.9% from 32.2M to 52.1M over 7 years.

See the SGHT income statement, the SGHT chart for price history, or the SGHT stock overview for the latest quote and news.

SGHT key metrics FAQ

What is Sight Sciences's return on equity?

Sight Sciences's return on equity (ROE) was −50.7% in fiscal 2025: net income of -$38.4 million on average shareholders' equity of $75.7 million.

What is Sight Sciences's ROIC?

Sight Sciences's return on invested capital was −289.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Sight Sciences have?

Sight Sciences had total debt of $40.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.64 and more cash than debt.

What is Sight Sciences's free cash flow yield?

Sight Sciences generated -$29.9 million of free cash flow in fiscal 2025, a free cash flow yield of −7.2% on its market value at year-end ($413.5 million).

What is Sight Sciences's current ratio?

Sight Sciences's current ratio was 10.22 at the end of fiscal 2025: current assets were 10.22 times current liabilities.

Medical Devices key metrics